Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus

Fertility and Sterility

Volumn 77, Issue 6, 2002, Pages 1095-1105

  Ovalle, Fernando ^a   Azziz, Ricardo ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Androgen excess; Diabetes; Glucose intolerance; Insulin resistance; Polycystic ovary syndrome

Indexed keywords

INSULIN;

AGE; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; ENDOCRINE SYSTEM; EPIDEMIOLOGICAL DATA; GENETIC DISORDER; HUMAN; HYPERINSULINEMIA; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MEDICAL LITERATURE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY; OVARY POLYCYSTIC DISEASE; PANCREAS; PHENOTYPE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REPRODUCTION; REVIEW; RISK ASSESSMENT;

DIABETES MELLITUS, TYPE 2; EUROPE; FEMALE; HUMANS; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; PREVALENCE; RISK FACTORS; TERMINOLOGY; UNITED STATES;

EID: 0036283724     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(02)03111-4     Document Type: Review

References (85)

1. Recent advances in our understanding of insulin action and insulin resistance
2. Consensus development conference on insulin resistance
3. Insulin resistance - Mechanisms, syndromes and implications
4. Cellular insulin action and insulin resistance
5. Pathogenesis of non-insulin-dependent diabetes mellitus
6. The short insulin tolerance test for determination of insulin sensitivity: A comparison with the euglycaemic clamp
7. Prevalence of insulin resistance in metabolic disorders. The Bruneck Study
8. Cardiovascular risk factors and hyperinsulinemia in elderly men: The Honolulu Heart Program
9. Insulin resistance and hypersecretion in obesity
10. Role of insulin resistance in human disease
11. Definition, diagnosis and classification of diabetes mellitus and its complications.: Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation
12. Metabolic consequences of a family history of NIDDM (the Botnia Study)
13. Cardiovascular morbidity and mortality associated with the metabolic syndrome
14. Prevalence of the metabolic syndrome among U.S. adults findings from the Third National Health and Nutrition Examination Survey
15. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach
16. Idiopathic hirsutism: An uncommon cause of hirsutism in Alabama
17. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?
18. Androgen parameters and their correlation with body weight in one hundred thirty-eight women thought to have hyperandrogenism
19. The prevalence and significance of elevated dehydroepiandrosterone sulfate levels in anovulatory women
20. Adrenal androgen excess in hyperandrogenism: Relationship of age and body mass
21. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease
22. Prolactin secretion in the polycystic ovary syndrome (PCO): Correlation with the steroid pattern
23. Hyperprolactinemia in the polycystic ovary syndrome
24. Epidemiology of infertility and polycystic ovarian disease: Endocrinological and demographic studies
25. Prevalence of the polycystic ovarian syndrome in unselected Black and White women of the southeastern United States: A prospective study
26. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile
27. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain
28. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome
29. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome
30. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome
31. Excessive insulin receptor phosphorylation in cultured fibroblasts and in skeletal muscle: A potential mechanism for insulin resistance in the polycystic ovary syndrome
32. Severe impairment of insulin action in adipocytes from amenorrheic subjects with polycystic ovary syndrome
33. Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity
34. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism
35. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system
36. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome
37. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease
38. Insulin resistance in nonobese patients with polycystic ovarian disease
39. Insulin resistance in polycystic ovary syndrome
40. Insulin secretion in obese and non-obese women with polycystic ovary syndrome and its relationship with hyperandrogenism
41. Metformin therapy in polycystic ovary syndrome reduced hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
42. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome
43. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
44. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
45. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome
46. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
47. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome
48. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double-blind, placebo-controlled trial
49. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome
50. Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion
51. Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction
52. Effect of weight loss and antiandrogenic therapy on sex hormone blood levels and insulin resistance in obese patients with polycystic ovaries
53. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
54. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
55. Impact of the new WHO classification and diagnostic criteria
56. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994
57. Comparison of diabetes diagnostic categories in the U.S. population according to 1997 ADA and 1985 WHO diagnostic criteria
58. Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites, and Hispanics with NIDDM: The Insulin Resistance Atherosclerosis Study
59. The day-to-day variation in insulin sensitivity in non-insulin-dependent diabetes mellitus patients assessed by the hyperinsulinemic-euglycemic clamp method
60. Le virilisme pilaire et son association a l'insuffisance glycolitique (diabete des fammes a barbe)
61. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance and/or hyperinsulinemia
62. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: A long-term follow-up focusing on natural history and circulating hormones
63. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women
64. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
65. Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients
66. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome
67. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome
68. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus
69. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome
70. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus
71. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus
72. The prevalence of polycystic ovaries in women with a history of gestational diabetes
73. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus
74. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes
75. Mechanism of insulin resistance in non-insulin-dependent (type II) diabetes
76. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome
77. Is insulin resistance the principal cause of type 2 diabetes?
78. Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus
79. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications
80. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative
81. Insulin secretion and insulin sensitivity in people with impaired glucose tolerance
82. Insulin action and secretion in healthy, glucose tolerant first degree relatives of patients with type 2 diabetes mellitus. Influence of body weight